Vendor Intelligence Report: BeiBangAn

Executive summary

Across 53 Finnrick lab tests, BeiBangAn shows 37 pass / 15 fail and an overall pass rate of 70%. The lab picture is uneven rather than uniformly bad. GHK-Cu is the best current signal, but on a thin sample base; Tirzepatide is the stronger mid-volume signal, Retatrutide has the most observations but a weaker rating, and BPC-157 is the clear avoid-or-test-first product. The methodology-divergence view matters here because stricter scoring shows how much the apparent rating depends on a forgiving frame.

The identity and recourse file is less forgiving. BBA presents like a manufacturer with long-history language, factory imagery, and China/California signals, but searched registries did not surface a matching BeiBangAn Biotechnology Co., Ltd. Current captures show the About Us claim softened while the homepage still keeps a long-history message and 2001 footer cue; the public Test Reports page is empty.

The operating trail points to a Telegram-first storefront that appeared after the SigmaAudley / SSA disruption. Forum records describe SSA-admin migration assistance and preserve a vendor-side acknowledgement that prior operator AkumaRift lied about an HGH test delay. Separate web evidence ties BBA assets and catalog overlap to LNPeptide, while a live Hong Kong SigmaAudley company record and a recent domain update remain unresolved watch items.

Inside the full report:

• Appendix A — Finnrick Laboratory Data with per-product pass/fail rates, trajectory charts, and methodology-divergence views for all 4 products
• Timeline tying late-2025 BBA launch to SigmaAudley / SSA forum records and AkumaRift references
• Registry and domain dossier for beibanganpeptides.com, beibangan.com, SigmaAudley (HK) Limited, and unresolved HK controller leads
• Side-by-side site captures showing softened About Us claims, continued long-history signals, and empty Test Reports page
• LNPeptide supply-chain analysis covering hyperlink, image-asset, and catalog-overlap evidence
• MESO-Rx and GLP-1 Forum evidence on HGH test-delay allegations, underdosing reports, and vendor-side acknowledgement

Risk assessment

• Batch-verification and adverse-test transparency risk — high: Empty Test Reports page and MESO-Rx admission that AkumaRift lied about HGH test delay leave buyers without batch-matched verification.
• Identity and manufacturer-claim risk — high: No BeiBangAn Biotechnology Co., Ltd. registration was found in searched registries; current site retains 25+ years and 2001-history signals inconsistent with domain history.
• Supply-chain traceability risk — high: BBA assets/catalog overlap LNpeptide, but BBA does not disclose a verifiable manufacturer, fill site, or chain-of-custody process.
• Predecessor-network and recourse risk — high: Forum records tie BBA launch to SSA admin AkumaRift; SigmaAudley (HK) Limited remains Live while BBA operates via privacy-protected/Telegram-first channels.
• HGH product-safety risk — high: MESO-Rx user reported repeated hypoglycemia after BBA HGH, with forum discussion of poor Janoshik HGH results and a vendor admission about lying on test delays.
• PT-141/SLU-PP-322 underdosing risk — high: Community Janoshik discussion reported BBA PT-141 10 mg at 5.9 mg and SLU-PP-322 5 mg at 2.62 mg.
• BPC-157 product-quality risk — high: Finnrick lists BPC-157 at 55.36% across 4 tests, the weakest current BBA product rating.
• Retatrutide/Tirzepatide product-quality inconsistency — medium: Finnrick lists Retatrutide at 71.44% across 29 tests and Tirzepatide at 75.56% across 15 tests, with meaningful failures in both products.